Latest Australian Government News

Papyrus Australia has taken significant strides in Q4 2024, signing a joint venture terms sheet in Vietnam, appointing new board members, and securing R&D tax incentives, positioning itself for expanded commercialization.

Arovella Therapeutics has bolstered its financial position with a $20 million placement, fully funding the Phase 1 clinical trial of its lead CAR-iNKT therapy, ALA-101, targeting CD19-positive blood cancers. The company also established a Clinical Advisory Board and anticipates key regulatory and clinical milestones in 2025.

Marquee Resources delivers a robust December quarter update, spotlighting strong drilling results at Redlings Rare Earth Project and a maiden Inferred Mineral Resource Estimate, while advancing exploration across multiple strategic projects.

Andromeda Metals has made significant strides in advancing its Great White Project, progressing funding efforts for Stage 1A+ and securing key operational milestones. The company also bolstered its leadership with new board appointments and received a substantial tax refund, positioning it for a critical investment decision.

Opthea Limited reports steady progress in its Phase 3 trials for sozinibercept, a novel treatment for wet AMD, supported by a strong cash position and a recent R&D tax incentive.

BCAL Diagnostics is poised to launch its innovative BREASTEST® breast cancer diagnostic test in early 2025, backed by recent NATA accreditation, patent acceptance, and a $2.6 million R&D tax offset.

Northern Minerals reports a 15% increase in its Wolverine Deposit resource and secures $28 million in funding, advancing its Browns Range heavy rare earths project amid ongoing feasibility studies.

Augustus Minerals reveals encouraging molybdenum and copper intersections from deep diamond drilling at Minnie Springs, highlighting promising mineralisation trends within its Ti-Tree Project.

VanEck Investments Limited has announced final dividends for a suite of its Australian and global bond ETFs, with payments scheduled for mid-February 2025. Investors are advised to note the ex-dividend dates and dividend reinvestment plan details.

GreenHy2 Limited reports a slight cash decline but strengthens its foothold in renewable energy with key partnerships and strategic pivots in hydrogen storage technology.

Optiscan Imaging Ltd has secured a $1.775 million R&D tax refund for FY24, more than doubling last year’s amount thanks to expanded claims on overseas research. The boost will fund ongoing development of its cutting-edge confocal laser endomicroscopy technology.

Dalaroo Metals advances its Lyons River Project with promising diamond drilling results confirming Broken Hill Type mineralisation and reports high-grade copper assays. The company also appoints Michael Brown as new MD and CEO, signaling a strategic push forward.